← FDA DRUG APPROVALS

FDA ANDA · ANDA065238

CEFOXITIN

Sponsor: HIKMA FARMACEUTICA

APPLICATION
ANDA065238
TYPE
ANDA
ORIGINAL APPROVAL
2010-03-12
LATEST ACTION
2019-12-30
ROUTE
INTRAVENOUS, INJECTION
DOSAGE FORM
INJECTABLE
MARKETING STATUS
Prescription

Products

CEFOXITINPrescription
CEFOXITIN SODIUM EQ 2GM BASE/VIAL · INJECTABLE · INJECTION
CEFOXITINPrescription
CEFOXITIN SODIUM EQ 1GM BASE/VIAL · INJECTABLE · INJECTION

Approval history

2019-12-30Labeling · Supplement 7 · standardAP
2019-12-30Labeling · Supplement 5 · standardAP
2019-12-30Labeling · Supplement 3 · standardAP
2010-03-12OriginalAP
VIEW ON DRUGS@FDA ↗

Related on SPEQ

Pharma industryGMP disciplineFDA drug shortagesFDA enforcement & recalls

Source: FDA Drugs@FDA. SPEQ is not affiliated with the FDA; this is a reference view of public FDA data, not medical, legal, or regulatory advice.

Weekly Briefing

Get the Weekly GxP Briefing

Curated regulatory intelligence — enforcement, recalls, guidance, and quality signals — in one practitioner-grade email each week. Free.

Read a past issue →